Preimplantation genetic testing for aneuploidy (PGT-A) typically involves a biopsy of cells from an embryo created through in vitro fertilization (IVF). These cells are then sent to a specialized genetics laboratory for analysis. The laboratory assesses the chromosomes of the embryo to identify any numerical abnormalities (too many or too few chromosomes), which can lead to implantation failure, miscarriage, or genetic conditions in the resulting child. The timeframe for analysis and reporting can vary depending on the specific laboratory techniques used and the laboratory’s workload.
This chromosomal screening provides valuable information that can help guide embryo selection for transfer during IVF, aiming to improve the chances of a successful pregnancy and a healthy baby. The development and refinement of PGT-A represents a significant advancement in reproductive medicine, offering prospective parents a way to mitigate some of the genetic risks associated with IVF and natural conception. This information empowers patients and healthcare providers to make informed decisions about their fertility journey.